Peregrine Initiates Dosing in Phase II Lung Cancer Trial
Posted on: Tuesday, 1 July 2008, 09:01 CDT
Peregrine Pharmaceuticals has initiated patient screening and dosing in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with non-small cell lung cancer.
The primary objective of the study is to assess the overall response rate to the combination of bavituximab with a standard regimen of carboplatin and paclitaxel in non-small cell lung cancer (NSCLC) patients. The multi-center clinical trial is being conducted in India.
In the trial's two-stage design, up to 21 patients with NSCLC will be enrolled initially. The study will then be expanded up to a total of 49 patients if promising results are observed in the initial cohort.
Secondary objectives of the study include time to tumor progression, duration of response, overall patient survival and safety parameters. Tumor response in the study will be evaluated using response evaluation criteria in solid tumors parameters. Patients may continue to receive bavituximab as long as the cancer does not progress and side effects are acceptable.
Steven King, president and CEO of Peregrine, said: "The initiation of patient enrollment and dosing in our trial of bavituximab in combination with chemotherapy in lung cancer patients marks an important milestone in our Phase II bavituximab clinical program."
Source: Datamonitor
Related Articles
- Baylor Sammons Cancer Center Joins One of Nation's Largest Cancer Clinical Trials Groups
- Cell Genesys Reports Updated Results From Phase 1 Clinical Trial of GVAX Immunotherapy for Prostate Cancer Used in Combination With Ipilimumab
- Revolution Health and EmergingMed Launch Cancer Clinical Trial Matching and Referral Service
- Pancreatic Cancer Therapy Trial Starts
- Study: Cancer Clinical Trials Lag Research
- Cell Therapeutics, Inc. (CTI) Closes PGT305 (PIONEER) Lung Cancer Clinical Trial; New PGT306 Protocol to Be Submitted to FDA By Year End
- Cell Therapeutics, Inc. (CTI) Temporarily Suspends Enrollment on PIONEER Lung Cancer Clinical Trial; Current Patients Continue to Be Treated
- Newsweek Hosts Special Capitol Hill Panel Discussion on 'The New Age of Cancer Clinical Trials: Issues and Opportunities'
- 17,500 Participants Needed to Enroll in Major Colorectal Cancer Clinical Trials; CancerTrialsHelp.Org Launches QuickLink
- Study looks at factors influencing African-American women's decisions to join cancer screening trial
 |
 |
User Comments (0)
RSS Feeds